Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.56 |
| ▸ | CA2 | P00918 | 17/20 | 0.56 |
| ▸ | CA9 | Q16790 | 17/20 | 0.56 |
| ▸ | CA12 | O43570 | 13/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 12/20 | 0.56 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176226 | 0.89 | CA1 (0.56) | CA1CA2CA9CA12CA14 | |
| SCHEMBL17993195 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19680843 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19680848 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL17964116 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL23319609 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19781238 | 0.86 | CA1 (0.47) | CA1CA2CA9CA12CA14 | |
| SCHEMBL3808545 | 0.85 | CA1 (0.50) | CA1CA2CA9CA12CA14 | |
| SCHEMBL9949556 | 0.80 | LGALS3 (0.56) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21175112 | 0.80 | CA1 (0.44) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424873-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | Forskarpatent I SYD AB (SE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126435-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | FORSKARPATENT I SYD AB (SE) | 2010-11-04 | — | — | WO | disclosed |